In 2023, the re-import of tetracyclines to China was USD 140.59 thousand. From 2024 to 2028, a declining trend is projected, with values dropping from USD 138.41 thousand in 2024 to USD 127.0 thousand in 2028. This indicates a consistent year-on-year decrease, averaging 2.0% per year.

Over the five-year period, the compound annual growth rate (CAGR) suggests a decline of approximately 2.0% per annum, reflecting a sustained downward trajectory in the re-import market.

Future trends to watch for:

Monitoring regulatory changes impacting antibiotic imports in China.
Assessing potential shifts in domestic production capabilities and preferences.
Observing global demand and supply chain adjustments that may affect import levels.